Skip to main navigation Skip to search Skip to main content

Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study

  • Lu Yan
  • , Maimaitijiang Wubuliaishan
  • , Xiaoni Kou
  • , Maimaitiaili Tuerxun
  • , Mingbo Yang
  • , Fanpu Ji
  • , Yingli He
  • , Jiuping Wang
  • , Longdong Zhu
  • , Xiaohong Gao
  • , Fuchun Jing
  • , Xiangchun Ding
  • , Hong Du
  • , Ye Zhang
  • , Hong Jiang
  • Tangdu Hospital, Fourth Military Medical University
  • Hotan Regional Infectious Diseases Hospital
  • The Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
  • Kashgar First People's Hospital
  • Xi'an No.8 Hospital (Shaanxi Infectious Diseases Hospital)
  • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Xi'an Jiaotong University
  • Xijing Hospital
  • The First Hospital of Lanchow University
  • Yan'an University
  • Ningxia Medical University

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

To assess the sustained virologic response (SVR12) and safety profile of 12-week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)-infected patients across genotypes in Northwest China. This prospective cohort study (2023–2024) enrolled HCV patients from 12 clinical centers in Northwest China, adhering to the China Hepatitis C Prevention Guidelines (2022). Participants received daily oral coblopasvir (60 mg) and sofosbuvir (400 mg) for 12 weeks. Key endpoints included HCV RNA quantification, genotype distribution, liver/kidney biomarkers, ultrasound findings, and liver stiffness measurements at baseline, end-of-treatment (EOT), and 12 weeks post-treatment (SVR12). Cirrhosis was defined by ultrasound and transient elastography (> 14.6 kPa). Of 209 initiators, 170 completed treatment (median age 52.5; 57.1% female), including 21 cirrhotic patients. Genotype distribution showed predominance of 1b (38.2%), 2a (31.2%), and 3a (12.4%), with rare 6a (0.6%) and untypable (2.4%). The EOT virologic clearance rate reached 98.8% (168/170), with SVR12 of 99.4% (128/129). Significant improvements occurred in liver biochemical indicators: ALT (p < 0.001), AST (p < 0.001), GGT (p < 0.001), TBil (p = 0.04 at SVR12). RBC increased (p = 0.04 at EOT; p = 0.00358 at SVR12). No renal impairment was observed (Cr, UA, UREA p > 0.05). The regimen demonstrated excellent tolerability with no severe adverse events. The COB/SOF combination achieved high SVR12 rates (> 99%) across diverse HCV genotypes in Northwest China, including cirrhotic patients, with concurrent liver function recovery and stable renal parameters. These real-world data support its first-line application in resource-limited regions.

Original languageEnglish
Article numbere70978
JournalJournal of Medical Virology
Volume98
Issue number5
DOIs
StatePublished - May 2026
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • coblopasvir
  • efficacy
  • pangenotypic regimen
  • safety
  • sofosbuvir
  • sustained virological response

Fingerprint

Dive into the research topics of 'Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study'. Together they form a unique fingerprint.

Cite this